Applied Therapeutics Inc APLT:NASDAQ

Last Price$1.72NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22

Today's Change-0.04(2.27%)
Bid (Size)$1.80 (1)
Ask (Size)$1.85 (20)
Day Low / High$1.71 - 1.93
Volume132.9 K

Sector Update: Health Care Stocks Finishing Lower in Monday Trading

4:04PM ET 1/03/2022 MT Newswires
Health care stocks trimmed a portion of its Monday retreat this afternoon, with the NYSE Health Care Index falling 1.1% while the SPDR Health Care Select Sector ETF (XLV) was down 1.2%.

The Nasdaq Biotechnology index, however, was rising 0.3%, reversing its midday decline.

In company news, Genmab (GMAB) was inching narrowly higher, rebounding from a nearly 1% slide earlier Monday followed a Guggenheim downgrade of the Danish oncology company to neutral from buy.

Applied Therapeutics (APLT) slumped Monday, at one point sinking almost 33% to a record low of $5.99 a share, after saying it placed a hold on the new drug application for its AT-007 drug candidate to treat galactosemia following discussions with the US Food and Drug Administration late last month. AT-007 currently is currently in a phase III trial.

Genprex (GNPX) was rising 164% just ahead of Monday's close, after the FDA issued a fast-track designation for a combination of its Reqorsa immunogene therapy and Merck's (MRK) Keytruda as a potential treatment for patients with unresectable stage three or stage four non-small cell lung cancer after preclinical data showed Reqorsa increased the presence of natural killer cells. The agency previously issued a fast-track designation for a combination of Reqorsa with AstraZeneca's (AZN) Tagrisso cancer medication.

Immix Biopharma (IMMX) earlier more than doubled in price on Monday, earlier rising 144% to a post-IPO high of $8.68 a share, after the US Food and Drug Administration granted a rare pediatric disease designation for IMX-110 drug candidate to treat rhabdomyosarcoma in children. The prospective cancer medication is currently in phase Ib/IIa testing.